Endocrine Abstracts

Background: Immune checkpoint inhibitors (ICPis) have become a cornerstone of cancer management. Whilst endocrine-related adverse effects are one of the most common immune-related adverse events, ICPi-induced de novo diabetes occurs at low frequencies1. We describe a case of ICPi-induced de novo type 1 diabetes presenting with severe diabetic ketoacidosis (DKA) in a female with metastatic melanoma.Case report: A 50-year-old l...